About MMVSola
An open tool for early dose and PK prediction
Sharing technology can spark innovation and accelerate the development of lifesaving medicines. This is why MMV has developed and made available a free tool for early prediction of (i) clinical pharmacokinetics (PK) (in malaria as well as other diseases) and (ii) the dose required to clear all parasites from an adult malaria patient weighing 50 kilograms. The tool aims to help teams optimize compound series and advance the selection of the best possible candidate drugs.
MMVSola was named to commemorate Suresh Solapure, a microbiologist and friend of MMV who tragically passed away in 2016. Suresh was an early champion of pharmacokinetic and pharmacodynamic (PKPD) data modelling to predict dose.
How it works
Validated, state-of-the art mathematical algorithms consolidate data from different preclinical experiments, seamlessly translating the results into predictions of the drug candidate’s exposure and effect on parasite dynamics. Using these predicted terms, a clinical dose is determined. The tool’s PK prediction function can be used not only in malaria, but in other therapeutic areas as well.
The tool is built using HTTPS (Hypertext Transfer Protocol Secure) encryption and data entered are not stored.
This means that for the first time, a freely accessible, encrypted application can be used to predict exposure, dosing and treatment durations for potential drug candidates as early as the discovery phase.
Criteria used for clinical antimalarial dose predictions
MMV has specific dose-prediction criteria for candidate drugs to give confidence that they will ultimately achieve the desired clinical outcome. Ideally, an estimated single dose of less than 500mg is the goal at this stage. MMVSola allows teams to confirm compounds are on track towards these criteria from the early discovery stages; it identifies which compound properties need to be optimized, and to what extent, to ultimately achieve this goal.
Streamlining and standardizing drug candidate identification
MMVSola can be used early, before investing in expensive and time-consuming experiments (though a minimum set of data are required). The greater the amount of data and the more advanced the compound, the greater the power of the tool in helping to discover and select the best possible candidates, and subsequently to design better and more informative clinical trials.
MMVSola integrates parameters established in the laboratory, including allowing predictions to be made without data from animal efficacy studies. This saves crucial resources, reduces the need for animal models and expedites drug development timelines.
The tool promotes the use of standardized drug discovery data, enabling laboratories to collaborate more effectively. All of MMV’s drug discovery projects use the MMVSola tool, thus enabling the comparison of compounds across the entire portfolio.
Intellectual property
MMVSola is free to use. However teams are requested to acknowledge MMV and to cite the link to MMVSola in any resulting publications.
Disclaimer: MMV accepts no liability for the use of the tool presented here, nor for the consequences of any action taken on the basis of the information generated by the tool.